Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 5/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26328548 | 0.83 | MEN1 (0.49) | MEN1KMT2ADNM1BCHEBACE1 | |
| SCHEMBL2111572 | 0.80 | KIF11 (0.50) | — | |
| SCHEMBL9170630 | 0.79 | ADRB2 (0.45) | MEN1KMT2ADNM1BCHEADRB2 | |
| SCHEMBL893963 | 0.78 | BCHE (0.63) | MEN1KMT2ADNM1BCHEBACE1 | |
| SCHEMBL2306548 | 0.78 | MAPT (0.60) | MEN1KMT2ADNM1BCHEADRB2 | |
| SCHEMBL1327171 | 0.78 | MAPT (0.60) | MEN1KMT2ADNM1BCHEADRB2 | |
| SCHEMBL17005472 | 0.78 | MAPT (0.60) | MEN1KMT2ADNM1BCHEADRB2 | |
| SCHEMBL24473808 | 0.76 | CA1 (0.60) | DNM1BCHEADRB2ADRB1ADRB3 | |
| SCHEMBL6322151 | 0.76 | ADRB1 (0.67) | MEN1KMT2AADRB2ADRB1ADRB3 | |
| SCHEMBL21759057 | 0.76 | ADRB1 (0.64) | MEN1KMT2AADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10835608-B2 | Polymer-carbohydrate conjugates for drug delivery technology | LIPOSEUTICALS INC | 2020-11-17 | — | — | US | disclosed |
| EP-3077006-B1 | POLYMER-CARBOHYDRATE CONJUGATES FOR DRUG DELIVERY TECHNOLOGY | WU NIAN (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-2673000-B1 | POLYMER-CARBOHYDRATE-LIPID CONJUGATES | WU NIAN (US) | 2018-05-16 | — | — | EP | disclosed |
| US-9175027-B2 | Polymer-carbohydrate-lipid conjugates | LIPOSEUTICALS, INC. | 2015-11-03 | — | — | US | disclosed |
| US-9175027-B2 | Polymer-carbohydrate-lipid conjugates | LIPOSEUTICALS, INC. | 2015-11-03 | — | — | US | disclosed |
| WO-2015085173-A1 | POLYMER-CARBOHYDRATE CONJUGATES FOR DRUG DELIVERY TECHNOLOGY | WU NIAN (US) | 2015-06-11 | — | — | WO | disclosed |
| US-20150157721-A1 | POLYMER-CARBOHYDRATE CONJUGATES FOR DRUG DELIVERY TECHNOLOGY | LIPOSEUTICALS INC | 2015-06-11 | — | — | US | disclosed |
| US-20150157721-A1 | POLYMER-CARBOHYDRATE CONJUGATES FOR DRUG DELIVERY TECHNOLOGY | LIPOSEUTICALS INC | 2015-06-11 | — | — | US | disclosed |
| WO-2012109112-A2 | POLYMER-CARBOHYDRATE-LIPID CONJUGATES | WU NIAN (US) | 2012-08-16 | — | — | WO | disclosed |
| WO-2012109052-A1 | POLYMER-CARBOHYDRATE-LIPID CONJUGATES | WU NIAN (US) | 2012-08-16 | — | — | WO | disclosed |
| US-20120202890-A1 | POLYMER-CARBOHYDRATE-LIPID CONJUGATES | WU NIAN (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202890-A1 | POLYMER-CARBOHYDRATE-LIPID CONJUGATES | WU NIAN (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202979-A1 | POLYMER-CARBOHYDRATE-LIPID CONJUGATES | LIPOSEUTICALS, INC. | 2012-08-09 | — | — | US | disclosed |
| US-20120202979-A1 | POLYMER-CARBOHYDRATE-LIPID CONJUGATES | LIPOSEUTICALS, INC. | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10835608-B2 | Polymer-carbohydrate conjugates for drug delivery technology | LIPC, FABP4, CETP | MEN1 2733/4885KMT2A 1977/4885DNM1 3164/4885 |
| US-20120202890-A1 | POLYMER-CARBOHYDRATE-LIPID CONJUGATES | LIPC, FUT6, UGCG | MEN1 1849/4885KMT2A 1692/4885DNM1 3061/4885 |
| US-20150157721-A1 | POLYMER-CARBOHYDRATE CONJUGATES FOR DRUG DELIVERY TECHNOLOGY | LIPC, FABP4, CETP | MEN1 2733/4885KMT2A 1977/4885DNM1 3164/4885 |
| US-20120202979-A1 | POLYMER-CARBOHYDRATE-LIPID CONJUGATES | LIPC, FUT6, UGCG | MEN1 1849/4885KMT2A 1692/4885DNM1 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.